This LTFU is being conducted to assess long-term safety and durability of response in participants dosed with IP in a parent protocol, and to collect longitudi…

Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn

~Estimated

~$10 – $1,050

iECURE, Inc.NCT06805695

Phase 2

A Phase 2a, Open-label, Multiple Ascending Dose Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency

Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.

OTC DeficiencyOrnithine Transcarbamylase DeficiencyOTCD

~Estimated

~$10 – $8,750

Arcturus Therapeutics, Inc.NCT06488313

Hepatic Histopathology in Urea Cycle Disorders

This is a multi-site, retrospective chart review as well as a prospective study to evaluate histopathologic findings in liver samples from individuals with any…

Urea Cycle DisorderOrnithine Transcarbamylase DeficiencyCitrullinemia 1+7 more

~Estimated

~$10 – $750

Baylor College of MedicineNCT04908319